Skip to content

Foresite Capital Management IV, LLC

Follow

13F filer, CIK 1704132, WEST HOLLYWOOD, CA

Foresite Capital Management IV, LLC reported $252,030,239 across 6 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.

Accepted , ingested 13F-HR 0001104659-26-128376

Period
2026-09-30
Reported value
$252M
Holdings
6
Top 10 weight
100%
New
1
Sold out
1

Part of the filer group Foresite Capital Management VI LLC

How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • IRLA QUINCE THERAPEUTICS INC: 13G 652,039 shares, 6% of the class, 13G filed 2026-10-14, 0001104659-26-115859Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VCYTnew+200,000$9.21M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CRNXexited-150,000-$5.61M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-128376, largest first. % of portfolio is the value over $252,030,239, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,397,881 shares; 2025Q1: 4,410,581 shares; 2025Q2: 4,410,581 shares; 2025Q3: 4,778,581 shares; 2025Q4: 4,778,581 shares; 2026Q1: 4,778,581 shares; 2026Q2: 4,778,581 shares; 2026Q3: 4,778,581 shares 4,778,581$152M60.14%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 458,295 shares; 2025Q4: 458,295 shares; 2026Q1: 503,295 shares; 2026Q2: 714,695 shares; 2026Q3: 714,695 shares 714,695$47.1M18.69%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,000,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,250,000 shares; 2026Q3: 1,250,000 shares 1,250,000$22.6M8.95%0Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,943,682 shares; 2026Q2: 1,943,682 shares; 2026Q3: 1,943,682 shares 1,943,682$15.6M6.2%0Timeline
VCYTVERACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 200,000 shares 200,000$9.21M3.65%newTimeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares; 2026Q2: 160,000 shares; 2026Q3: 160,000 shares 160,000$5.95M2.36%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CRNXCRINETICS PHARMACEUTICALS IN150,000$5.61Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-128376 base2026-11-16